Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine
Gabriella Lupo(University of Catania), Carmelina Daniela Anfuso(University of Catania), Nunzia Caporarello(Mayo Clinic), Carla Motta(University of Catania), Vincenzo Bramanti(University of Catania), Roberto Avola(University of Catania), Mario Salmeri(University of Catania), Martina Cristaldi(University of Catania), Ferdinando Nicoletti(University of Catania), Melania Olivieri(University of Catania)
Cited by 84
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
GSK-3 as potential target for therapeutic intervention in cancer
|Oncotarget|2014|508
The neuropathic pain: An overview of the current treatment and future therapeutic approaches
|International Journal of Immunopathology and Pharmacology|2019|495